Screener
Summit Therapeutics SMMT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $647,856 | $751,182 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $27,549 | $20,292 |
| Accrued liabilities | 44,317 | 32,100 |
| Accrued compensation | 7,073 | 14,925 |
| Operating lease liabilities, current portion | 3,179 | 3,388 |
| Other current liabilities | 1,148 | 2,283 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's accounts payable?
- Summit Therapeutics (SMMT) reported accounts payable of $27.55M in Q1 2026.
- How has Summit Therapeutics's accounts payable changed year-over-year?
- Summit Therapeutics's accounts payable increased by 451.6% year-over-year, from $4.99M to $27.55M.
- What is the long-term trend for Summit Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Summit Therapeutics's accounts payable has grown at a 27.0% compound annual growth rate (CAGR), from $6.14M to $20.29M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Summit Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude